Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

(2021) Anthony T. Tan et al.   Cell Reports

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

(2021) Victoria Jane Hall et al.   LANCET

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

(2021) Amy Flaxman et al.   LANCET

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

(2021) Angela Choi et al.   NATURE MEDICINE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

(2021) Kizzmekia S. Corbett et al.   SCIENCE

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

(2021) Daryl Geers et al.   Science Immunology

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

(2021) Sara Y Tartof et al.   LANCET

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

(2021) Noam Barda et al.   LANCET

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

(2021) Koen B. Pouwels et al.   NATURE MEDICINE

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

(2020) Wei Deng et al.   SCIENCE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

From Vaccines to Memory and Back

(2010) Federica Sallusto et al.   IMMUNITY